Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition
ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition alone. We determined the cytotoxicity of the ATR inhibitor VE-821 in isogenically matched cells with DDR imbalance. Cell cycle arrest, DNA damage accumulation and repair were determined following VE-821 exposure.Defects in homologous recombination repair (HRR: ATM, BRCA2 and XRCC3) and base excision repair (BER: XRCC1) conferred sensitivity to VE-821. Surprisingly, the loss of different components of the trimeric non-homologous end-joining (NHEJ) protein DNA-PK had opposing effects. Loss of the DNA-binding component, Ku80, caused hypersensitivity to VE-821, but loss of its partner catalytic subunit, DNA-PKcs, did not. Unexpectedly, VE-821 was particularly cytotoxic to human and hamster cells expressing high levels of DNA-PKcs. High DNA-PKcs was associated with replicative stress and activation of the DDR. VE-821 suppressed HRR, determined by RAD51 focus formation, to a greater extent in cells with high DNA-PKcs.Defects in HRR and BER and high DNA-PKcs expression, that are common in cancer, confer sensitivity to ATR inhibitor monotherapy and may be developed as predictive biomarkers for personalised medicine.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2015 |
|---|---|
| Erschienen: |
2015 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:6 |
|---|---|
| Enthalten in: |
Oncotarget - 6(2015), 32 vom: 20. Okt., Seite 32396-409 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Middleton, Fiona K [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.08.2016 Date Revised 13.11.2018 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.18632/oncotarget.6136 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM253867967 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM253867967 | ||
| 003 | DE-627 | ||
| 005 | 20231224171138.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.18632/oncotarget.6136 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0846.xml |
| 035 | |a (DE-627)NLM253867967 | ||
| 035 | |a (NLM)26486089 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Middleton, Fiona K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition |
| 264 | 1 | |c 2015 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.08.2016 | ||
| 500 | |a Date Revised 13.11.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a ATR is an attractive target in cancer therapy because it signals replication stress and DNA lesions for repair and to S/G2 checkpoints. Cancer-specific defects in the DNA damage response (DDR) may render cancer cells vulnerable to ATR inhibition alone. We determined the cytotoxicity of the ATR inhibitor VE-821 in isogenically matched cells with DDR imbalance. Cell cycle arrest, DNA damage accumulation and repair were determined following VE-821 exposure.Defects in homologous recombination repair (HRR: ATM, BRCA2 and XRCC3) and base excision repair (BER: XRCC1) conferred sensitivity to VE-821. Surprisingly, the loss of different components of the trimeric non-homologous end-joining (NHEJ) protein DNA-PK had opposing effects. Loss of the DNA-binding component, Ku80, caused hypersensitivity to VE-821, but loss of its partner catalytic subunit, DNA-PKcs, did not. Unexpectedly, VE-821 was particularly cytotoxic to human and hamster cells expressing high levels of DNA-PKcs. High DNA-PKcs was associated with replicative stress and activation of the DDR. VE-821 suppressed HRR, determined by RAD51 focus formation, to a greater extent in cells with high DNA-PKcs.Defects in HRR and BER and high DNA-PKcs expression, that are common in cancer, confer sensitivity to ATR inhibitor monotherapy and may be developed as predictive biomarkers for personalised medicine | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a ATR | |
| 650 | 4 | |a DNA damage response | |
| 650 | 4 | |a DNA-PKcs | |
| 650 | 4 | |a p53 | |
| 650 | 4 | |a synthetic lethality | |
| 650 | 7 | |a 3-amino-6-(4-(methylsulfonyl)phenyl)-N-phenylpyrazine-2-carboxamide |2 NLM | |
| 650 | 7 | |a Antineoplastic Agents |2 NLM | |
| 650 | 7 | |a MYC protein, human |2 NLM | |
| 650 | 7 | |a Nuclear Proteins |2 NLM | |
| 650 | 7 | |a Protein Kinase Inhibitors |2 NLM | |
| 650 | 7 | |a Proto-Oncogene Proteins c-myc |2 NLM | |
| 650 | 7 | |a Pyrazines |2 NLM | |
| 650 | 7 | |a Sulfones |2 NLM | |
| 650 | 7 | |a ATR protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a Ataxia Telangiectasia Mutated Proteins |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a DNA-Activated Protein Kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a PRKDC protein, human |2 NLM | |
| 650 | 7 | |a EC 2.7.11.1 |2 NLM | |
| 650 | 7 | |a DNA Repair Enzymes |2 NLM | |
| 650 | 7 | |a EC 6.5.1.- |2 NLM | |
| 700 | 1 | |a Patterson, Miranda J |e verfasserin |4 aut | |
| 700 | 1 | |a Elstob, Claire J |e verfasserin |4 aut | |
| 700 | 1 | |a Fordham, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Herriott, Ashleigh |e verfasserin |4 aut | |
| 700 | 1 | |a Wade, Mark A |e verfasserin |4 aut | |
| 700 | 1 | |a McCormick, Aiste |e verfasserin |4 aut | |
| 700 | 1 | |a Edmondson, Richard |e verfasserin |4 aut | |
| 700 | 1 | |a May, Felicity E B |e verfasserin |4 aut | |
| 700 | 1 | |a Allan, James M |e verfasserin |4 aut | |
| 700 | 1 | |a Pollard, John R |e verfasserin |4 aut | |
| 700 | 1 | |a Curtin, Nicola J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Oncotarget |d 2010 |g 6(2015), 32 vom: 20. Okt., Seite 32396-409 |w (DE-627)NLM199620113 |x 1949-2553 |7 nnns |
| 773 | 1 | 8 | |g volume:6 |g year:2015 |g number:32 |g day:20 |g month:10 |g pages:32396-409 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.18632/oncotarget.6136 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 6 |j 2015 |e 32 |b 20 |c 10 |h 32396-409 | ||